Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

18.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 67
Open 18.92
Bid (Size) 18.88 (1)
Ask (Size) 19.47 (1)
Prev. Close 18.92
Today's Range 18.92 - 18.92
52wk Range 18.02 - 38.00
Shares Outstanding 62,027,061
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets

Performance

YTD
-46.14%
-46.14%
1 Month
-8.22%
-8.22%
3 Month
-2.72%
-2.72%
6 Month
-29.93%
-29.93%
1 Year
-30.80%
-30.80%

More News

Read More
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
What Analysts Are Saying About Schrodinger Stock
Via Benzinga
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Via Talk Markets
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
From Schrödinger
Via Business Wire
The 3 Best Med Tech Stocks to Buy Now
Via InvestorPlace
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Schrödinger Reports Strong Second Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
3 Small-Cap Stocks to Buy at a 52-Week Low
Via InvestorPlace
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
From Schrödinger
Via Business Wire
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
Simulations Plus Stock Drops 15% Despite EPS Beat
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Top-Rated Gene Editing Stocks Actually Making Money
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.